肝病患者血清脯氨酸肽酶活性检测的临床应用  

Clinical application to measurement of serum prolidase activity in liver disease patients

作　　者：张吉林[1] 宋玉国[2] 

机构地区：[1]北华大学医学院分子生物学教研室,吉林吉林132013 [2]北华大学生物医学研究所,吉林吉林132011

出　　处：《临床荟萃》2007年第7期467-469,共3页Clinical Focus

摘　　要：目的研究血清脯氨酸肽酶活性在肝病中的应用价值。方法采用酶促反应终点法检测了50例健康人和137例肝病患者血清脯氨酸肽酶活性。结果脯氨酸肽酶的正常参考范围为(854.64±191.79)U/L,肝病各组脯氨酸肽酶水平显著高于正常对照组(P<0.01);经过治疗后各组肝病患者脯氨酸肽酶水平均比治疗前降低(P<0.01);当脯氨酸肽酶水平持续高于2 500 U/L时,肝硬化患者存活率为28.57%,而当脯氨酸肽酶水平稳定在1 800U/L以下时,存活率为94.12%(P<0.01)。结论血清脯氨酸肽酶活性的检测可估测肝病患者的病情、评价疗效和判断肝硬化患者的预后。Objective To research application of serum prolidase （PLD） activity in the liver disease. Methods An endpoint method of enzymatic reaction was used to detect serum PLD activity in 50 healthy subjects and in 137 patients with hepatic disease. Results Normal PLD reference range is （854.64±191.79） U/L,and there were much higher levels in different types of liver diseases than those in normal control group （ P 〈0.01）. After therapy, PLD levels in different types of liver diseases were lower than before （ P 〈0.01）. Survival rates of the patients with liver cirrhosis were 28.57% when PLD levels kept the level at higher than 2 500 U/L,but survival rates were 94.12% while PLD levels remained lower than 1 800 U/L（ P〈0.01）. Conclusion The measurement of PLD activity may be used to assess the state of an illness, evaluate curative effect and make prognosis in the patients with cirrhosis.

关 键 词：肝炎 乙型 脯氨酸肽酶 终点法 

分 类 号：R512.62[医药卫生—内科学]